Convergence Investment Partners’s PDL BioPharma, Inc. PDLI Stock Holding History

Convergence Investment Partners’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-107,980	Closed	-$339K	–	427
2016 Q2	$339K	Buy	+107,980	New	+$360K	0.05%	290
2016 Q1	–	Sell	-444,724	Closed	-$1.57M	–	428
2015 Q4	$1.57M	Buy	444,724 +115,674	+35%	+$484K	0.18%	190
2015 Q3	$1.66M	Buy	329,050 +11,814	+4%	+$67.7K	0.19%	173
2015 Q2	$2.04M	Buy	317,236 +117,616	+59%	+$788K	0.2%	169
2015 Q1	$1.4M	Buy	199,620 +105,630	+112%	+$765K	0.2%	205
2014 Q4	$725K	Sell	93,990 -51,960	-36%	-$411K	0.1%	289
2014 Q3	$1.09M	Hold	145,950	–	–	0.15%	211
2014 Q2	$1.41M	Buy	145,950 +21,700	+17%	+$193K	0.19%	178
2014 Q1	$1.03M	Sell	124,250 -168,954	-58%	-$1.45M	0.16%	188
2013 Q4	$2.48M	Buy	293,204 +276,154	+1,620%	+$2.33M	0.4%	83
2013 Q3	$136K	Hold	17,050	–	–	0.03%	305
2013 Q2	$132K	Buy	+17,050	New	+$133K	0.03%	306

Other funds holding PDLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $70.2B AUM 29.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Convergence Investment Partners's PDLI Position: Q3 2016 in Review

Convergence Investment Partners sold out of PDL BioPharma, Inc. (PDLI) in Q3 2016, closing a stake of 107,980 shares — an estimated $339K sold.

Convergence Investment Partners first reported a position in PDLI in Q2 2013 and held it in 12 quarters. The position peaked at $2.48M in Q4 2013. 197 funds tracked by Wall St. Rank hold PDLI as of Q3 2016.

Convergence Investment Partners reported no remaining PDL BioPharma, Inc. position as of Q3 2016 after selling out during the quarter.
Convergence Investment Partners sold 107,980 PDL BioPharma, Inc. shares in Q3 2016, an estimated $339K.
Convergence Investment Partners first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 12 quarters.
Convergence Investment Partners's PDL BioPharma, Inc. position peaked at $2.48M in Q4 2013.
197 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2016.

Based on Convergence Investment Partners's 13F filing for Q3 2016, filed 10 Nov 2016.